GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

TDSPharm Co 464280.KQ · KRW

N/A · KOSDAQ · 🇰🇷 South Korea

Compare

4,000

-4.99%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩27.62bn

FY2021FY2025

Net income

₩4.27bn

FY2021FY2025

Free cash flow

−₩9.10bn

FY2021FY2025

Shareholders' equity

₩42.78bn

FY2021FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021
Revenue₩27.62bn₩27.52bn₩30.05bn₩25.59bn₩19.82bn
Gross profit₩7.50bn₩7.72bn₩8.96bn₩7.43bn₩5.22bn
Research and development₩665.9m₩622.5m₩441.2m₩478.8m₩356.1m
Operating income₩3.77bn₩3.73bn₩5.02bn₩3.87bn₩2.50bn
Net income₩4.27bn₩3.72bn₩4.69bn₩3.46bn₩2.06bn
Diluted earnings per share808.27703.00979.00721.65390.06

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Total assets₩54.15bn₩49.16bn₩33.97bn₩30.47bn₩26.97bn
Cash and short-term investments—₩30.70bn₩15.14bn₩9.94bn—
Total liabilities₩11.37bn₩10.66bn₩11.03bn₩12.16bn₩10.82bn
Debt—₩6.07bn₩6.87bn₩6.85bn—
Shareholders' equity₩42.78bn₩38.50bn₩22.94bn₩18.31bn₩16.14bn
Shares outstanding5m5m5m5m5m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021
Cash from operations₩3.78bn₩3.93bn₩3.29bn₩2.94bn₩3.68bn
Capital spending−₩12.88bn−₩717.4m−₩271.4m−₩630.9m−₩200.9m
Free cash flow−₩9.10bn₩3.21bn₩3.02bn₩2.31bn₩3.48bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₩7.98bn₩7.98bn₩8.63bn₩8.03bn₩5.53bn₩5.27bn₩5.62bn₩6.47bn
Gross profit₩1.91bn₩2.27bn₩2.48bn₩2.55bn₩1.30bn₩1.18bn₩1.44bn₩1.89bn
Operating income₩1.04bn₩1.34bn₩1.61bn₩1.64bn₩323.3m₩188.7m₩297.3m₩846.5m
Net income₩959.0m₩1.15bn₩1.59bn₩1.46bn₩859.0m₩366.4m₩595.8m₩846.7m
Diluted earnings per share181.34216.77300.48276.09162.4369.27112.65160.10
Cash from operations₩1.55bn₩2.29bn₩794.0m₩1.89bn−₩34.0m₩1.13bn₩3.93bn₩4.81bn
Capital spending−₩52.0m−₩412.0m−₩11.93bn−₩167.0m−₩735.0m−₩53.0m−₩717.0m−₩467.0m
Free cash flow₩1.49bn₩1.88bn−₩11.13bn₩1.72bn−₩769.0m₩1.07bn₩3.21bn₩4.34bn
Total assets₩63.71bn₩62.01bn₩54.15bn₩51.51bn₩49.99bn₩48.54bn₩49.16bn₩50.33bn
Cash and short-term investments—————₩28.45bn—₩31.87bn
Debt—————₩6.06bn—₩6.06bn
Shareholders' equity₩44.89bn₩43.93bn₩42.78bn₩41.19bn₩39.73bn₩38.87bn₩38.50bn₩37.91bn

Financial ratios

Data as of 17 Sept 2026

FY2025FY2024FY2023FY2022FY2021
Gross margin27.2%28.1%29.8%29.0%26.3%
Operating margin13.6%13.6%16.7%15.1%12.6%
Net margin15.5%13.5%15.6%13.5%10.4%
Return on equity10.0%9.7%20.4%18.9%12.8%
Return on assets7.9%7.6%13.8%11.3%7.6%
Revenue growth0.4%-8.4%17.4%29.1%—
Earnings growth15.0%-20.7%35.7%67.5%—
Current ratio2.66x3.77x2.43x1.83x1.37x
Debt to equity—0.16x0.30x0.36x—
Equity ratio79.0%78.3%67.5%60.1%59.9%
Interest coverage16.90x13.93x16.64x17.53x19.26x
R&D as a share of sales2.4%2.3%1.5%1.9%1.8%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue2.3%——
Operating income-0.9%——
Net income7.3%——

Average margins

Over each period

1 year3 years5 years10 years
Gross margin27.6%28.5%——

Valuation history

At each fiscal year end

FY2025FY2024
Price to earnings12.218.8
Price to sales1.92.5

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.